Bioton przejmie singapurski SciGen

[Gość: irkiel]

Szczerze mowiac jestem w szoku!!!!

[Gość: biotech]

po co im ta singapuska firma? pewnie tylko do tego aby w mednaich bylo glosno o
firmie, ze 'podbija' azjatycki rynek, za pare mln zlotych... ehh.. to ta firma
to chyba 5 osob i jedno male laboratorium...

[Gość: starycynik]

Ta singapurska firma ma 12.5 mln zlotych przychodu rocznie czyli 3.84 mln
dolarow rocznie czyli 10500 dolarow dziennie. Galon benzyny to 3 dolary czyli
firma ma utarg 3500 galonow benzyny. Do baku wchodzi 14 galonow czyli wystarczy
jak zatankuje 250 samochodow. Tyle daje mala stacja benzynowa, ktora oprocz
tego sprzedaje papierosy i cole. Odnosze wrazenie ze pisanie gigant
biotechnologiczny jest pewna przesada.

[brunoski]

Sydeny - Thursday - February 17: (RWE) Directors of SciGen Limited have
announced the company has received health care registration for its insulin
product SciLinTM in the Philippines.

According to World Health Organisation statistics, over 2 million Filipinos are
diagnosed as having diabetes, with a large number of the population remaining
undiagnosed. The Philippines ranks 10th in the list of countries with the
highest incidence of diabetes in the world.

Preparations are well underway for the sales launch of SciLinTM in the
Philippines to occur as soon as possible.

SciLinTM is a second generation recombinant human insulin that SciGen has the
exclusive rights to market in the Asia Pacific Region.

Managing director and CEO Mark Compton said, "We are delighted with yet another
regulatory approval for SciLinTM. This provides SciGen with not only an
expanded market for the product, but also a real opportunity to assist in
treating the dramatically escalating problem of diabetes amongst Filipinos."
SciLinTM is currently registered and sold by SciGen or its partners in India,
Vietnam and Pakistan.

Shares of SciGen slipped 0.1c to 5.5c today.

[brunoski]

a na gieldzie ASX 27 wrzesnia
SCIGEN LTD (SIE) 0.047 +0.001 +2.17 (Last up/dn % move)

[brunoski]

9 wrzesnia

The board of SciGen Limited (SciGen) announced the reappointment of the company
executive vice chairman and founder Saul Mashaal Phmb, MBA, to the position of
CEO.

In addition to his CEO responsibility Mashaal will continue to be responsible
for the business development, in and out-licensing, research and development (R
& D) and manufacturing.

Mashaal has more than 30 years experience in the pharmaceutical industry first
with Syntex Corporation in product management and later with 3M Health &
Sciences Sector where he had a long and successful career in various
disciplines including clinical research and international business development.

In 1988 he founded SciTech Genetics in Singapore and in 1999 all of SciTech
Genetics product portfolio of BioPharmaceutical products were transferred to
what is now SciGen. Soon after SciGen attracted major investors such as Sonic
Healthcare and more recently Bioton. He remained the CEO of SciGen until
September 2001 when the executive management was transferred to Australia.

[Gość: ams]

Nie ważne czy to gigant, ważne że ma licencje na sprzedaż leków na rynek
azjatycki! Bioton kópił licencję a rynek azjatycki jest bardzo chłonny więc
według mnie to bardzo dobra decyzja.